⚠ Evidence warning: Clinical trials or other evidence do not support the claim that cumin works like a mild statin (by raising liver LDL-receptor activity and blocking HMG-CoA reductase), raises the body's metabolic rate and preferentially removes visceral (deep belly) fat. This page keeps it as a report of what people, websites or other media say.

Cumin for Cholesterol and Weight

Cholesterol and Weight — scientific infographic poster

The cumin-and-cardiometabolic literature includes several randomized controlled trials and two meta-analyses. The most-discussed trial is Zare R et al. 2014, Complementary Therapies in Clinical Practice, "Effect of cumin powder on body composition and lipid profile in overweight and obese women." 88 overweight or obese women in Iran were randomized to 3 grams of cumin powder a day with yogurt at two meals, or the same amount of yogurt without cumin, for 3 months, and all of them received nutrition counselling for weight loss. Cumin powder reduced fasting cholesterol, triglycerides and low-density lipoprotein (LDL) cholesterol and increased high-density lipoprotein (HDL) cholesterol; weight, body mass index, waist circumference and fat mass fell significantly; there was no effect on fasting blood sugar. A proposed mechanism is upregulation of liver low-density lipoprotein-receptor expression and partial inhibition of HMG-CoA reductase — the pathway statins target — but no study of cumin has shown it. Cumin is not a statin replacement; it is a low-cost spice that has been tested as a dietary addition in people with excess weight and abnormal blood fats.


Table of Contents

  1. Zare 2014 — The Foundational Cholesterol Trial
  2. Detailed Results — Weight, Lipids, Glucose
  3. Trial Design Strengths and Limitations
  4. What the Pooled Trials Show
  5. Low-Density Lipoprotein-Receptor Upregulation Mechanism
  6. HMG-CoA Reductase Inhibition — The Statin Pathway
  7. Triglyceride Reduction Mechanism
  8. Weight Loss — Proposed Mechanisms
  9. Why Yogurt as the Vehicle — Bioavailability Considerations
  10. Clinical Positioning vs Statins, Fibrates, and Lifestyle
  11. The Trial Regimen and Everyday Use
  12. Cautions and Drug Interactions
  13. Key Research Papers
  14. Connections
  15. Featured Videos

Zare 2014 — The Foundational Cholesterol Trial

Zare R, Heshmati F, Fallahzadeh H, Nadjarzadeh A (2014). "Effect of cumin powder on body composition and lipid profile in overweight and obese women." Complementary Therapies in Clinical Practice, volume 20, issue 4, pages 297–301. It is one of several randomized trials of cumin for weight and blood fats. The full paper was not available to check, so the design below is given as the published abstract describes it.

Study design:

Both arms received the same dietary advice and weight-loss counseling, so the differential effect attributable to cumin is the increment over what dietary counseling alone produced. This is a methodologically sound design that addresses the most common confounder in nutraceutical weight-loss trials (the "Hawthorne effect" of being in a trial driving lifestyle changes independently of the active intervention).

Back to Table of Contents

Detailed Results — Weight, Lipids, Glucose

The published abstract reports the outcomes after 3 months in words rather than figures:

The size of each change is not given in the abstract, and the full paper was not available to check, so this page does not give figures for this trial.

The high-density lipoprotein increase is particularly notable — few interventions reliably increase high-density lipoprotein by clinically meaningful amounts. Most statins produce small high-density lipoprotein increases (5–10%); fibrates produce larger increases (10–20%); niacin at high dose produces the largest (25–35%). The Zare abstract reports an HDL increase with cumin but does not give its size.

Back to Table of Contents

Trial Design Strengths and Limitations

Strengths of the Zare 2014 trial:

Limitations to acknowledge:

None of the limitations are fatal. The Zare trial is good-quality evidence for a moderate cumin effect on lipids and weight when added to standard dietary advice in overweight subjects. Larger, multi-center, longer-duration confirmatory trials would strengthen the evidence base further. The Blood Sugar deep-dive page covers cumin and glucose.

A second, double-blind trial (2016) gave 72 overweight adults aged 18–50 capsules of cumin plus lime at a high dose (75 mg each), a low dose (25 mg each) or placebo, twice daily for eight weeks. Compared with the low dose and placebo, the high dose produced significant weight loss (−2.1 kg, against −1.2 kg on the low dose and +0.2 kg on placebo) and significant falls in fasting plasma glucose, triglycerides, total cholesterol and LDL cholesterol.

Not every trial was positive. A 2019 triple-blind trial gave 56 people with metabolic syndrome 75 mg of cumin essential oil or a placebo soft gel three times daily for 8 weeks. At the end, the groups differed only in diastolic blood pressure (81.41 vs 84.09 mmHg); weight and other body measures, blood sugar, blood fats and insulin resistance did not differ, and the authors concluded that the oil had no effect on the metabolic syndrome components except diastolic blood pressure.

Back to Table of Contents

What the Pooled Trials Show

A 2025 GRADE-assessed meta-analysis pooled nine randomized trials published between 2013 and 2020, lasting 8 to 24 weeks, in adults with metabolic disorders. Cumin significantly lowered fasting blood sugar, triglycerides and waist circumference and raised HDL cholesterol, but results varied widely between trials (heterogeneity I² up to 94.6%), and the authors state that further high-quality, large-scale trials are needed to confirm the findings.

A 2022 meta-analysis of eight randomized trials found that cumin lowered body mass index (by 0.88 kg/m²) and total cholesterol (by 3.96 mg/dL). It did not show an overall effect on LDL cholesterol, although a subgroup of trials lasting more than 8 weeks suggested a benefit for LDL.

Back to Table of Contents

Low-Density Lipoprotein-Receptor Upregulation Mechanism

The proposed mechanism for cumin's low-density lipoprotein-lowering effect is upregulation of hepatic low-density lipoprotein-receptor (LDLR) expression. The low-density lipoprotein receptor is the principal mechanism by which circulating low-density lipoprotein particles are cleared from blood — the receptor binds the apolipoprotein B-100 on the low-density lipoprotein particle's surface and internalizes the entire complex, where it is digested in lysosomes and the cholesterol content is released for cellular use or storage.

Hepatic LDLR expression is regulated by sterol regulatory element binding protein 2 (SREBP-2), which in turn responds to intracellular cholesterol concentration. When intracellular cholesterol is low, SREBP-2 is cleaved and translocated to the nucleus where it activates transcription of LDLR (to bring more cholesterol into the cell) and HMG-CoA reductase (to synthesize more cholesterol de novo). When intracellular cholesterol is high, SREBP-2 is retained in the ER membrane and LDLR transcription decreases.

Statins work by inhibiting HMG-CoA reductase, reducing intracellular cholesterol synthesis, which paradoxically increases LDLR expression via SREBP-2 release — the increased LDLR then pulls more low-density lipoprotein from circulation, lowering serum low-density lipoprotein. The same mechanism applies to bile acid sequestrants (cholestyramine), which lower intracellular cholesterol by forcing increased bile acid synthesis from cholesterol substrate.

It has been proposed that cumin's essential-oil monoterpenes engage this same pathway, by partial HMG-CoA reductase inhibition and by effects on SREBP-2 activation; no study showing this for cumin (Cuminum cyminum) is known, so it remains a hypothesis. For scale, a 2003 meta-analysis of 164 placebo-controlled trials found that atorvastatin 10 mg/day, lovastatin 40 mg/day, simvastatin 40 mg/day or rosuvastatin 5 mg/day lowered LDL cholesterol by 1.8 mmol/l (40%). The 2022 cumin meta-analysis did not show an overall LDL effect of cumin.

Back to Table of Contents

HMG-CoA Reductase Inhibition — The Statin Pathway

HMG-CoA reductase is the rate-limiting enzyme of cholesterol biosynthesis. It converts HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) to mevalonate, the first committed step in the multi-step pathway that ultimately produces cholesterol. Statin drugs (atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin) are competitive HMG-CoA reductase inhibitors — they bind the enzyme with much higher affinity than the natural substrate, blocking cholesterol synthesis.

Several plant compounds have been shown to inhibit HMG-CoA reductase, though at much lower potency than pharmacologic statins:

If cumin does act on HMG-CoA reductase, that would probably be only a portion of any lipid effect, with LDLR upregulation and increased bile-acid excretion (via the cholagogue effect discussed on the Digestive Aid deep-dive) proposed as additional routes.

Back to Table of Contents

Triglyceride Reduction Mechanism

The Zare trial reported reductions in both triglycerides and LDL cholesterol, and triglyceride lowering also appears in the pooled analyses. Mechanisms proposed specifically for triglyceride metabolism include:

Triglyceride elevations in the 200–500 mg/dL range are common in metabolic syndrome and pre-diabetes, often under-treated because they don't reach the fibrate-indicated severe range (>500 mg/dL with pancreatitis risk). In the 2025 meta-analysis, cumin lowered triglycerides in adults with metabolic disorders. Other approaches used in this range include omega-3 fatty acids (which produce 20–30% TG reduction at 2–4 g/day eicosapentaenoic acid (EPA)+docosahexaenoic acid (DHA)), dietary carbohydrate reduction, and weight loss.

Back to Table of Contents

Weight Loss — Proposed Mechanisms

The Zare trial reported significant reductions in weight, waist circumference and fat mass with cumin over 3 months, on top of the nutrition counselling both groups received; in the 2016 capsule trial the high dose gave −2.1 kg against +0.2 kg on placebo over eight weeks. Several mechanisms have been proposed:

None of these effects is large in isolation. The weight changes in the trials were modest, and they were achieved with a low-cost dietary addition.

Back to Table of Contents

Why Yogurt as the Vehicle — Bioavailability Considerations

Zare 2014 used yogurt as the cumin delivery vehicle. The fat content of whole-milk yogurt (3 – 5%) is thought to improve the absorption of cumin's lipophilic essential-oil monoterpenes. Cuminaldehyde, p-cymene, alpha-pinene, and the other key actives are fat-soluble; taking cumin powder dry with water is thought to give poorer absorption than taking it with a fat-containing food vehicle.

Yogurt also provides the practical advantage of acceptability and compliance. 3 g of cumin powder eaten dry is unpleasant; stirred into yogurt at two meals, as in the trial, it becomes a savory yogurt snack taken for 3 months. The yogurt may also provide additional health benefits independently (calcium, probiotic content, satiety from protein), though the Zare design gave the same amount of yogurt to the control group so these effects would have washed out in the between-group comparison.

Alternative high-bioavailability vehicles include:

The common factor across these vehicles is fat content sufficient to dissolve the essential-oil monoterpenes. Dry cumin in tea or water is acceptable for the digestive-aid and acute-effect indications but probably suboptimal for the cardiometabolic indications where systemic absorption matters more.

Back to Table of Contents

Clinical Positioning vs Statins, Fibrates, and Lifestyle

For more on cardiovascular risk assessment and management, see our Cardiology page.

Back to Table of Contents

The Trial Regimen and Everyday Use

What the Zare trial used, and how it compares with everyday use:

Back to Table of Contents

Cautions and Drug Interactions

Back to Table of Contents

Key Research Papers

  1. Zare R, Heshmati F, Fallahzadeh H, Nadjarzadeh A (2014). Effect of cumin powder on body composition and lipid profile in overweight and obese women. Complementary Therapies in Clinical Practice, 20(4), 297–301. — PubMed PMID: 25456022
  2. Taghizadeh M et al. (2016). The effect of cumin cyminum L. plus lime administration on weight loss and metabolic status in overweight subjects: a randomized double-blind placebo-controlled clinical trial. Iranian Red Crescent Medical Journal. — PubMed PMID: 27781121
  3. Dhandapani S et al. (2002). Hypolipidemic effect of Cuminum cyminum L. on alloxan-induced diabetic rats. Pharmacological Research. — PubMed PMID: 12220968
  4. Sambaiah K, Srinivasan K (1991). Effect of cumin, cinnamon, ginger, mustard, and tamarind in induced hypercholesterolemic rats. Nahrung. — PubMed PMID: 1865890
  5. Morovati A, Pourghassem Gargari B, Sarbakhsh P (2019). Effects of cumin (Cuminum cyminum L.) essential oil supplementation on metabolic syndrome components: a randomized, triple-blind, placebo-controlled clinical trial. Phytotherapy Research, 33(12), 3261–3269. — PubMed PMID: 31478290
  6. Kazemipoor M, Hamzah S, Hajifaraji M, Radzi CW, Cordell GA (2016). Slimming and appetite-suppressing effects of caraway aqueous extract as a natural therapy in physically active women. Phytotherapy Research, 30(6), 981–987. (Caraway, a close cumin relative) — PubMed PMID: 26988309
  7. Liu M, Wu S, Falahatzadeh M (2025). Potential benefits of Cuminum cyminum L supplementation on components of metabolic syndrome in adults with metabolic disorders: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials. Frontiers in Nutrition, 12, 1618108. — PubMed PMID: 41608519
  8. Tavakoli-Rouzbehani OM, Faghfouri AH, Anbari M, Nikpayam O, PourMirzaei Olyaei H, Alizadeh M (2022). Efficacy of Cuminum cyminum supplementation on lipid profile and anthropometric parameters: a systematic review and meta-analysis of randomized controlled clinical trials. Phytotherapy Research, 36(1), 380–394. — PubMed PMID: 34825421
  9. Law MR, Wald NJ, Rudnicka AR (2003). Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ, 326(7404), 1423. — PubMed PMID: 12829554

PubMed Topic Searches

  1. PubMed: Cumin cholesterol and lipids
  2. PubMed: Cumin weight loss RCTs
  3. PubMed: Cumin HMG-CoA reductase
  4. PubMed: Cumin metabolic syndrome
  5. PubMed: Spices LDL receptor and SREBP

Back to Table of Contents

Connections

Back to Table of Contents